Table 3.
Locus | Allele frequency |
Genotype frequency |
|||||
---|---|---|---|---|---|---|---|
UMOD | PDILT | UMOD | PDILT | ||||
Population | N | rs4293393 | rs12917707 | rs12446492 | rs4293393 | rs12917707 | rs12446492 |
1000 Genomes Project | |||||||
Global | 2504 | T: 80.0%a C: 20.0% |
G: 90.2%a T: 9.8% |
T: 42.3%a A: 57.7% |
TT: 65.1% CT: 29.9% CC: 5.0% |
GG: 82.1% GT: 16.1% TT: 1.8% |
TT: 20.4% AT: 43.8% AA: 35.8% |
African | 661 | T: 80.7%a C: 19.3% |
G: 97.7%a T: 2.3% |
T: 50.2%a A: 49.8% |
TT: 65.2% CT: 31.0% CC: 3.8% |
GG: 95.5% GT: 4.5% TT: 0% |
TT: 26.8% AT: 46.9% AA: 26.3% |
European | 503 | T: 79.9%a C: 20.1% |
G: 79.9%a T: 20.1% |
T: 55.8%a A: 44.2% |
TT: 64.4% CT: 31.0% CC: 4.6% |
GG: 64.4% GT: 31.0% TT: 4.6% |
TT: 32.4% AT: 46.7% AA: 20.9% |
African-PREDICT Study | |||||||
Total population | 1202 | T: 74.5%a C: 25.5% |
G: 88.6%a T: 11.4% |
T: 45.5%a A: 53.5% |
TT: 55.7% CT: 37.6% CC: 6.7% |
GG: 78.6% TG: 20.0% TT: 1.4% |
TT: 21.8% TA: 49.4% AA: 28.8% |
Black | 606 | T: 67.5%a C: 32.5% |
G: 93.8%a T: 6.2% |
T: 37.2%a A: 62.8% |
TT: 45.0% CT: 45.0% CC: 10.0% |
GG: 87.8% TG: 12.0% TT: 0.2% |
TT: 13.0% TA: 48.2% AA: 38.7% |
White | 596 | T: 81.6%a C:18.4% |
G: 83.3%a T: 16.7% |
T: 55.9%a A: 44.1% |
TT: 66.5% CT: 30.1% CC: 3.4% |
GG: 69.3% TG: 28.1% TT: 2.6% |
TT: 30.5% TA: 50.7% AA: 18.8% |
PURE study | |||||||
Black | 1943 | T: 66.0%a C: 34.0% |
G: 94.4%a T: 5.6% |
T: 40.5%a A: 59.5% |
TT: 43.6% CT: 44.8% CC: 11.6% |
GG: 88.9% TG: 11.0 % TT: 0.1% |
TT: 15.1% TA: 50.8% AA: 34.1% |
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
For rs4293393, alleles T/C on the reverse strand are reported.
rs4293393 (UMOD), rs12917707 (UMOD), and rs12446492 (PDILT) have been strongly associated with urinary levels of uromodulin, eGFR, and risk of CKD in European cohorts.8,9,20,21 In these studies, kidney-protective alleles and/or UMOD expression reducing alleles are the European minor alleles rs4293393(C), rs12917707(T), and rs12446492(A).
Refers to the European “CKD risk” SNP.